David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.
@ILSONDavid @sloan_kettering @mskcc #ASCO21 #ColorectalCancer #GastrointestinalCancer
– Colorectal Cancer and Gastrointestinal Cancer-
Link to Abstract 4000 – ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
https://meetinglibrary.asco.org/record/195933/abstract
Link to Abstract LBA4001 – Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
https://meetinglibrary.asco.org/record/195919/abstract
Link to Abstract 4002 – First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
https://meetinglibrary.asco.org/record/195932/abstract
Link To Abstract 4003 – Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
https://meetinglibrary.asco.org/record/195939/abstract
Link to Abstract 4004 – Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
https://meetinglibrary.asco.org/record/195929/abstract
Link to Abstract TPS4161 – A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).
https://meetinglibrary.asco.org/record/201239/abstract
Link to Abstract – Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
https://meetinglibrary.asco.org/record/195968/abstract
Link to Abstract – A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
https://meetinglibrary.asco.org/record/191807/abstract
Link to Abstract – Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
https://meetinglibrary.asco.org/record/185549/abstract
Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center, Harvard Medical School.
@ABhealer108 @MGHCancerCenter @MassGeneral @MassGeneralNews #Breast Cancer #Cancer #Research
– Breast Cancer –
Link to Abstract – OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
https://meetinglibrary.asco.org/record/115571/abstract
Link to Abstract – Significantly different costs of adjuvant chemotherapy regimens in the United States.
https://meetinglibrary.asco.org/record/60336/abstract
Link to Abstract – Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
https://meetinglibrary.asco.org/record/196389/abstract
Link to Abstract – KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
https://meetinglibrary.asco.org/record/165258/abstract
Link to Abstract – Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.
https://meetinglibrary.asco.org/record/199969/abstract
Link to Abstract – Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
https://meetinglibrary.asco.org/record/198455/abstract
Link to Abstract – Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
https://meetinglibrary.asco.org/record/195728/abstract
Link to Abstract – Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
https://meetinglibrary.asco.org/record/195726/abstract
Link to Abstract – AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
https://meetinglibrary.asco.org/record/198207/abstract
Link to Abstract – Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
https://meetinglibrary.asco.org/record/195726/abstract
Howard ‘Jack’ West, MD, Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research at the City of Hope.
@JackWestMD @cityofhope @cancerGRACE #ASCO21
– Lung Cancer –
Link to Abstract 8500- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/195950/abstract
Link to Abstract 8503 – Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/195951/abstract
Link to Abstract 9001 – Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.
https://meetinglibrary.asco.org/record/196990/abstract
Link to Abstract 9003 – Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
https://meetinglibrary.asco.org/record/196931/abstract
Link to Abstract 9006 – Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC), and potential biomarkers for response.
https://meetinglibrary.asco.org/record/196820/abstract
Link to Abstract 9007 – Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/196836/abstract
Link to Abstract 9004 – Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
https://meetinglibrary.asco.org/record/197070/abstract
Link to Abstract 9005 – Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
https://meetinglibrary.asco.org/record/198284/abstract
Link to Abstract 9013 – Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
https://meetinglibrary.asco.org/record/198410/abstract
Link to Abstract 8517 – Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.
